In DepthBiomedicine

Targeting copper to treat breast cancer

See allHide authors and affiliations

Science  10 Jul 2015:
Vol. 349, Issue 6244, pp. 128-129
DOI: 10.1126/science.349.6244.128

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

A drug, tetrathiomolybdate (TM), which mops up copper in the body and that had already failed in a series of previous cancer clinical trials, is getting a second chance. A phase II trial of the drug in women who had been successfully treated for breast cancer but have a high risk of recurrence suggests that it can prevent the growth of new tumors. Yet the promise of this copper depletion strategy appears tarnished—not by clinical results but by corporate strategy. The oncologist who led the phase II trial now wants to proceed with a larger, phase III trial of TM. But the rights to treating cancer with TM are held by a Swedish biotech company that is developing the drug instead for Wilson disease, a rare inherited disease of copper accumulation. The company, Wilson Therapeutics, has no immediate plans to test TM in cancer patients, its CEO acknowledges, and for now will not sublicense the drug.

  • * Ken Garber is a writer based in Ann Arbor, Michigan.